Skin Hypersensitivity and Precipitating Antibodies Against Allergic Bronchopulmonary Aspergillosis

Amtul Naseer¹, *, Hafiz Anwaar UL Huda², Khalida Naseem³

1 Department of Pharmacy, Superior University Lahore, Pakistan
2 College of Pharmacy, University of Sargodha, Sargodha Pakistan
3 Department of Chemistry, Faculty of Sciences, University of Central Punjab, Lahore, Pakistan
Correspondence: E-mail: amtulsham@yahoo.com

Abstracts
Allergic bronchopulmonary aspergillosis (ABPA) is a very fatal disease and more than four million people have been affected. We collected data of forty-five patients and a skin hypersensitivity test was performed. We also evaluated precipitating antibodies against Aspergillus fumigatus. Instant hypersensitivity reactions were recorded in 22.22% of patients and 6.66% displayed delayed type III reaction. 4.44% of patients exhibited precipitin bands and three infections of ABPA among 45 infected people. A literature survey was also made to understand Aspergillus fumigatus.

Article Info
Article History:
Received 04 Aug 2021
Revised 08 Sep 2021
Accepted 10 Sep 2021
Available online 12 Sep 2021

Keyword:
Allergic,
Aspergillus fumigatus,
Education,
Health,
Lung.
1. INTRODUCTION

Allergic bronchopulmonary aspergillosis (ABPA) is a severe and scarce disease that exists not only in Pakistan but all over the world. Prior bronchial asthma (BA) is the key agent for the occurrence of the disease and *Aspergillus fumigatus* generates the hypersensitivity of the skin. Mostly, BA patients are infected with this disorder and also those patients who are suffering from cystic fibrosis. Pulmonary insinuates bronchospasm and immunological indications prove the existence of *Aspergillus* class antigens (Patterson & Strek, 2010; Stevens et al., 2000; Beswick et al., 2020; Murrison et al., 2019).

*Aspergillus* species are present in the surroundings universally and affect the natural habitats in various positive and negative ways including humans. There are more than hundreds of species of *Aspergillus* that exist in the universe and only some species cause diseases in humans, animals, and plants. Humans are infected broadly by the *Aspergillus* infections and the host immune system is responsible to respond to these infections if the host immune system will be strong, the reaction will not be severe and if it will be weak, hypersensitivity reaction will be fatal (Paulussen et al., 2017; Rokas et al., 2020). ABPA is mostly caused by the *Aspergillus* fungal agent which is a very communal aerial fungus. It reaches easily to the pulmonary tracts and attaches there because of its very small size and diameter and causes infection. Asthmatic people are very affected by the ABPA and also those who have some sort of allergy to *Aspergillus*. These fungal spores are strongly attached to the inner pulmonary lining due to the thick mucus in the airways (Denning et al., 2011; Kramer et al., 2015; Knutsen et al., 2012; Denning et al., 2006). Genetic variations, associations, and environmental factors also affect the ABPA infection level and asthma condition. ABPA disease is present in all the indivual irrespective of age but mostly it affects more to peoples at the 3rd to 5th stage of life. Children are also infected by this disease. Asthmatic patients with severe conditions are mostly suffering from the fatal disease of ABPA. **Figure 1** helps to understand the main features of the Aspergillus disease (Eng et al., 2016; Agarwal et al., 2013; Polosa et al., 2008).

There is not all demonstration of the *Aspergillus* pathogen is present in the literature it is not easy to understand pathogenicity effect in the patients (Carsin et al., 2017). The spores which are inserted inside the pulmonary veins through inhalation caused allergic effects. The advanced studies also show that people with strong immune can eradicate these fungal microbes and remain healthy. In contrast, people with weak immune are not able to eliminate and these infect the allergic effect causing the development of IgG and IgE antibodies, and hypersensitivity effect is induced by the helping T cells. The reaction of hypersensitivity is stimulated and promoted by the pro-inflammatory cytokines transfer that disarrays the protecting layer of the cell and causes cell damage (Humbert et al., 2019).
Aspergillus Disease

Figure 1. Aspergillus disease.

There is a multifaceted cytoplasmic association, a remarkable morphological expression array, and an astounding assorted and malleable metabolism. The fungus is capable of attack tissue following inward breath. Hyphal sections hold fast to endothelial cells and discharge an assortment of chemicals that aid further tissue intrusion and obtaining of supplements. During propagation, foundation, and attack, Aspergillus retort and adjust to different sorts of stressors, oxygen, and nitrogen deficiency (Abad et al., 2010).

The nature of unrefined concentrates for finding and treatment is exceptionally unacceptable in the contagious concentrate’s incidents. Right now, the nature of form extricates fluctuates drastically between entrepreneurs' suppliers since no typical excerpts are present (Agarwal et al., 2016). The explanations behind the deficient quality are complex. From one viewpoint, unrefined concentrates from various growths have been appeared to differ significantly in their protein synthesis. These issues are brought about by varieties among strains and bunch-to-clump varieties (Tracy et al., 2016). Furthermore, mild extracts might be delivered from mycelial cells or potentially spores, which may change in their protein design. In the development conditions, protein extraction strategies and capability situations are basic regarding the amount and even presence of individual antigens. Conclusively, disparagement of the extricated proteins may happen (Øya et al., 2019).

Somewhat, the issues with fungal extracts might be overwhelmed by the utilization of recombinant antigens. The significant points of interest of recombinant proteins over unrefined parasitic extracts are triple. Firstly, the protein arrangements are reproducible. Secondly, the creation of enormous amounts of unadulterated proteins is conceivable. Thirdly, utilizing recombinant allergens, it is conceivable to separate among co-appearance, co-refinement, and cross-reactivity (Asano et al., 2021).

Over time, diagnostic studies have analyzed recombinant parasitic proteins and rough shape extricates as for their negative and positive consistency of form sharpening and sickness. There is an enormous number of antigens have been disseminated for the Aspergillus fumigatus. Since Aspergillus fumigatus is especially known for its wide range of

DOI: [http://dx.doi.org/10.17509/xxxx.xxxx](http://dx.doi.org/10.17509/xxxx.xxxx)
p- ISSN 2775-6793 e- ISSN 2775-6815
human problems, numerous specialists have expected to discover a connection between a
given infection and the patients' reactivity example to singular recombinant allergens.

One-fourth of asthmatic and half of the cystic fibrosis infected individuals are allergic to
Aspergillus but ABPA is not considerably ubiquitous. ABPA is a very fatal disease and more
than 40 lacs people have been infected till now. The organism which mostly causes the ABPA
is known as Aspergillus fumigatus. This fungus remains at the dead hydrocarbons of organic
substances and endures. The highest infection rate in the world is recorded in the winter
season after the falling leaves from the trees. There are a lot of ABPA cases are reported every
season. Our study also demonstrates the hypersensitivity stimulation and frequency of the
individual's group to Aspergillus fumigatus.

2. MATERIAL AND METHODS

Forty individuals having bronchial asthma were selected for the study and all were adults.
Every case was completely examined, studied and a brief history of the patient was evaluated.
Brown plugs history was observed in the sputum recurrent febrile and variation in the
radiological forms were inquired and evaluated. Other allergic syndromes were also noted in
all the patients for better results and cross-examination. The intake of corticosteroids was
also noticed in the current or past duration. Chest skiagram was performed to count all
leucocytes with sputum culture and the entire count of eosinophil. The intracutaneous
injection was inserted on the forearm by using Aspergillus fumigatus to accomplish the skin
tests. Steroid intake was stopped before 7 days of the skin test while anti asthmatics drugs
were not taken for two to three days. The reaction was controlled by expanding the buffer of
saline. Ouchterlonys gel diffusion technique was used to determine precipitins' presence in
sera of infected individuals against the antigens of Aspergillus niger, Aspergillus flavus, and
Aspergillus fumigatus. Rosenberg criteria were used for the diagnose of ABPA and IgE levels
were not recorded.

3. RESULTS

We examined the forty-five patients and among these 45 patients, 25 males and 20
females were investigated. 60% of patients belonged to the urban area while 40% were from
rural backgrounds. Mean of all the patient's ages measured which value was 31 ranging
from lower age limit of 20 to the highest age limit of 55 years. The average period of asthmatic
disease was six years. Allergic associations were present in eighteen patients (40%), two had
urticaria (4.44%), and three had eczema (6.66%).

We summarized all the clinical and laboratory evidence of the patients in Table 1. Ten out
of forty-five infected peoples (22.22%) had positivity in skin infection tests and type III
reaction was deferred in three patients (6.66%) among these patients. More than two
precipitin bands of Aspergillus fumigatus were found in three out of forty-five patients
(6.66%) and precipitins alongside Aspergillus fumigatus were discovered in two cases (4.44%)
and one (2.22%). against the Albicans.

Four patients report showed that they had positivity of precipitin and skin reactivity and in
this way, a combined dual result was measured. The sputa of 22 patients were imperiled to
fungal culture and candida Albicans were generated in the five cases. Aspergillus was
produced in the three patients. The laboratory findings and clinical data of three patients
(6.66%) out of forty-five cases are summarized in Table 2.
Table 1. Laboratory and clinical Findings of bronchial asthma patients (n=45).

| Studied factors | Number | %   |
|-----------------|--------|-----|
| Age < 30 years (Onset respiratory disorder) | 37/45 | 82.22 |
| H/O airway obstruction | 33/45 | 73.33 |
| Blood eosinophils | 11/25 | 44.00 |
| Recurrent febrile episodes | 3/45 | 6.66 |
| H/O expectorating brown specks | 3/45 | 6.66 |
| Patchy opacities | 2/28 | 14.00 |
| Sputum culture positive for Aspergillus fumigatus | 1/25 | 4.00 |
| Aspergillus fumigatus and skin hypersensitivity | 10/45 | 22.22 |
| Type III responses vs Aspergillus fumigatus | 3/45 | 6.66 |
| Precipitin bands on immunodiffusion vs Aspergillus fumigatus | 2/45 | 4.44 |

Table 2. Laboratory and clinical findings of the viable Aspergillosis patients.

| Sex | Age | Skin test | Sputum | Eosinophils | Positive precipitins | Steroid intake | Comment |
|-----|-----|-----------|--------|-------------|----------------------|----------------|---------|
| F   | 43  | Dual +    | Aspergillus fumigatus + Candida albicans | 1700 | Candida albicans | 4 years but not continuously | Asthma depends on steroid |
| M   | 39  | Dual +    | No development | 2150 | Aspergillus fumigatus | 5 years | Bronchogram has proximal bronchiectasis Persistent pneumonias |
| M   | 40  | Dual +    | Aspergillus flavus + | 2100 | Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus | 2.5 years | Persistent pneumonias |

4. DISCUSSION

Although, many data and reports have been published in the Pakistani literature about the ABPA existence and infections in the people in the country. We have also collected and published a small data report because of the increase in Aspergillus infections and the number of patients has raised a lot. There is a positive rate of 40-60% skin hypersensitivity to Aspergillus found in the literature of various countries. ABPA is an extreme kind of hypersensitive asthma that happens in around 10% of patients with stern asthma. Although a mixture of foundational corticosteroids and against parasitic specialists is a standard treatment, there is a danger of side effects with long-term utilization of fundamental corticosteroids (Bourdin et al., 2020). Our study did not reveal the relationship with age, gender, asthma period, and treatment with steroid and plasma eosinophils. Specifically, our data showed that there were three potential cases (6.66%) of unfavorably susceptible bronchopulmonary aspergillosis among these 45 patients and less manifestation of the precipitin positivity was due to steroid consumption.
5. CONCLUSION

We collected data of forty-five patients and a skin hypersensitivity test was performed. We also evaluated precipitating antibodies against *Aspergillus fumigatus*. Instant hypersensitivity reactions were recorded in 22.22% of patients and 6.66% displayed delayed type III reaction. 4.44% of patients exhibited precipitin bands and three infections of ABPA among 45 infected people. A literature survey was also made to understand *Aspergillus fumigatus*.

6. AUTHORS’ NOTE

The authors declare that there is no conflict of interest regarding the publication of this article. Authors confirmed that the paper was free of plagiarism.

7. REFERENCES

Patterson, K. and Strek, M. E. (2010). Allergic bronchopulmonary aspergillosis. *Proceedings of the American Thoracic Society, 7*(3), 237-244.

Stevens, D. A., Schwartz, H. J., Lee, J. Y., Moskovitz, B. L., Jerome, D. C., Catanzaro, A., Bamberger, D. M., Weinman, A. J., Tuazon, C. U., Judson, M. A., Platts-Mills, Y. A. E. and DeGraff Jr, A. C. (2000). A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. *New England Journal of Medicine, 342*(11), 756-762.

Beswick, E., Amich, J. and Gago, S. (2020). Factoring in the complexity of the cystic fibrosis lung to understand *Aspergillus fumigatus* and Pseudomonas aeruginosa interactions. *Pathogens, 9*(8), 639.

Murrison, L. B., Brandt, E. B., Myers, J. B. and Hershey, G. K. K. (2019). Environmental exposures and mechanisms in allergy and asthma development. *The Journal of clinical investigation, 129*(4), 1504-1515.

Paulussen, C., Hallsworth, J. E., Álvarez-Pérez, S., Nierman, W. C., Hamill, P. G., Blain, D., Rediers, H. and Lievens, B. (2017). Ecology of aspergillosis: Insights into the pathogenic potency of *Aspergillus fumigatus* and some other Aspergillus species. *Microbial Biotechnology, 10*(2), 296-322.

Rokas, A., Mead, M. E., Steenwyk, J. L., Oberlies, N. H. and Goldman, G. H. (2020). Evolving moldy murderers: *Aspergillus* section Fumigati as a model for studying the repeated evolution of fungal pathogenicity. *PLoS Pathogens, 16*(2), e1008315.

Denning, D. W. and Perlin, D. S. (2011). Azole resistance in *Aspergillus*: A growing public health menace. *Future Microbiology, 6*(11), 1229-1232.

Kramer, R., Sauer-Heilborn, A., Welte, T., Guzman, C. A., Abraham, W. R. and Höfle, M. G. (2015). Cohort study of airway mycobiome in adult cystic fibrosis patients: Differences in community structure between fungi and bacteria reveal predominance of transient fungal elements. *Journal of Clinical Microbiology, 53*(9), 2900-2907.

Knutsen, A. P., Bush, R. K., Demain, J. G., Denning, D. W., Dixit, A., Fairs, A., Greenberger, P. A., Kariuki, B., Kita, H., Kurup, V. P., Moss, R. B., Niven R. M., Pashley, C. H., Slavin, R. G., Vijay. H. M. and Wardlaw, A. J. (2012). Fungi and allergic lower respiratory tract diseases. *Journal of Allergy and Clinical Immunology, 129*(2), 280-291.

DOI: [http://dx.doi.org/10.17509/xxxx.xxxx](http://dx.doi.org/10.17509/xxxx.xxxx)
p- ISSN 2776-6098 e- ISSN 2776-5938
Denning, D. W., O'driscoll, B. R., Hogaboam, C. M., Bowyer, P. and Niven, R. M. (2006). The link between fungi and severe asthma: a summary of the evidence. European Respiratory Journal, 27(3), 615-626.

Eng, S. S. and DeFelice, M. L. (2016). The role and immunobiology of eosinophils in the respiratory system: A comprehensive review. Clinical Reviews in Allergy and Immunology, 50(2), 140-158.

Agarwal, R., Hazarika, B., Gupta, D., Aggarwal, A. N., Chakrabarti, A. and Jindal, S. K. (2010). Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA?. Medical Mycology, 48(7), 988-994.

Bongomin, F., Gago, S., Oladele, R. O. and Denning, D. W. (2017). Global and multi-national prevalence of fungal diseases—estimate precision. Journal of Fungi, 3(4), 57.

Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss. R., Denning. D. W. and ABPA Complicating Asthma ISHAM Working Group. (2013). Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy, 43(8), 850-873.

Polosa, R. (2008). An overview of chronic severe asthma. Internal Medicine Journal, 38(3), 190-198.

Carsin, A., Romain, T., Ranque, S., Reynaud-Gaubert, M., Dubus, J. C., Mège, J. L. and Vitte, J. (2017). Aspergillus fumigatus in cystic fibrosis: An update on immune interactions and molecular diagnostics in allergic bronchopulmonary aspergillosis. Allergy, 72(11), 1632-1642.

Singh, M., Paul, N., Singh, S. and Nayak, G. R. (2018). Asthma and fungus: Role in allergic bronchopulmonary aspergillosis (ABPA) and other conditions. The Indian Journal of Pediatrics, 85(10), 899-904.

Humbert, M., Bousquet, J., Bachert, C., Palomares, O., Pfister, P., Kottakis, I., Jaumont, X., Thomsen, S. F. and Papadopoulos, N. G. (2019). IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. The Journal of Allergy and Clinical Immunology: In Practice, 7(5), 1418-1429.

Carrillo-Muñoz, A. J., Quindós, G. and Lopez-Ribot, J. L. (2004). Current developments in antifungal agents. Current Medicinal Chemistry-Anti-Infective Agents, 3(4), 297-323.

Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., Sknov. M., Maish. W., Mastella. G. and Participants in the Cystic Fibrosis Foundation Consensus Conference. (2003). Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases, 37(3), S225-S264.

Abad, A., Fernández-Molina, J. V., Bikandi, J., Ramírez, A., Margareto, J., Sendino, J., Hernando, F. L., Ponton, J., Garaizar, J. and Rementeria, A. (2010). What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis. Revista Iberoamericana De Micologia, 27(4), 155-182.
Agarwal, R., Sehgal, I. S., Dhooria, S. and Aggarwal, A. N. (2016). Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. *Expert Review of Respiratory Medicine, 10*(12), 1317-1334.

Tracy, M. C., Okorie, C. U., Foley, E. A. and Moss, R. B. (2016). Allergic bronchopulmonary aspergillosis. *Journal of Fungi, 2*(2), 17.

Øya, E., Becher, R., Ekeren, L., Afanou, A. K., Øvrevik, J. and Holme, J. A. (2019). Pro-inflammatory responses in human bronchial epithelial cells induced by spores and hyphal fragments of common damp indoor molds. *International Journal of Environmental Research and Public Health, 16*(6), 1085.

Asano, K., Hebisawa, A., Ishiguro, T., Takayanagi, N., Nakamura, Y., Suzuki, J., Okada. N., Tanaka. J., Fukutomi. Y., Ueki. S., Fukunaga. K., Konno. S., Matsuse. H., Kamei. K., Tanaguchi. M., Shimoda. T., Oguma. T. and Program, J. A. R. (2021). New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. *Journal of Allergy and Clinical Immunology, 147*(4), 1261-1268.

Souza, J. A. M., Baltazar, L. D. M., Carregal, V. M., Gouveia-Eufrasio, L., Oliveira, A. G. D., Dias, W. G. and Soriani, F. M. (2019). Corrigendum: Characterization of aspergillus fumigatus extracellular vesicles and their effects on macrophages and neutrophils functions. *Frontiers in Microbiology, 10*, 2334.

Kwon-Chung, K. J. and Sugui, J. A. (2013). *Aspergillus fumigatus*—what makes the species a ubiquitous human fungal pathogen?. *PloS Pathogens, 9*(12), e1003743.

Pegorie, M., Denning, D. W. and Welfare, W. (2017). Estimating the burden of invasive and serious fungal disease in the United Kingdom. *Journal of Infection, 74*(1), 60-71.

Michaels, R. A. (2017). Environmental Moisture, Molds, and Asthma—Emerging Fungal Risks in the Context of Climate Change. *Environmental Claims Journal, 29*(3), 171-193.

Bourdin, A., Adcock, I., Berger, P., Bonniaud, P., Chanson, P., Chenivesse, C., Blic. J. D., Deschildre. A., Devillier. P., Devouassoux. G., Didier. A., Garcia. G., Magnan. A., Martinat. Y., Perez. T., Roche. N., Taillé. C., Val. P. and Chanez, P. (2020). How can we minimise the use of regular oral corticosteroids in asthma?. *European Respiratory Review, 29*(155).